A recent study showed that adavosertib (AZD1775), in combination with the Chk1 inhibitor prexasertib (LY2606268), showed high cytotoxicity against HPV-negative HNSCC with a compromised G1/S checkpoint caused by TP53 mutations (121). This evidence concerns the gene CHEK1 and head and neck squamous cell carcinoma.